BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
KRChoksey Research Report
Aurobindo Pharma Ltd.'s reported revenue de-growth of 8.4% YoY (up 4.2% QoQ) to Rs 59.42 billion, due to decline in the growth markets (Africa, Canada, Brazil and China) and in antiretroviral and active pharma ingredient segments, which was partially offset by growth in the U.S. and Europe.
Ebitda for the quarter declined 17.2% YoY (down 1.9% QoQ) to Rs 11.87 billion while Ebitda margin declined 213 bps YoY (down 124 bps QoQ) to 20.0% in Q2 FY22.
This has largely been due to increased prices of key raw materials and increased logistics costs and research and development expenses.
Aurobindo Pharma's reported net profit declined 13.7% YoY to Rs 6.97 billion mainly on account of decline in YoY sales coupled with contractions in gross profit margin and increased other operating expenses in Q2 FY22.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
As a Subscriber you get
Stories
RECOMMENDED FOR YOU
POPULAR